2142.HK in “China Becomes Pharma's Global R&D Engine”
HBM Holdings Limited
Harbour BioMed's antibody-discovery platforms and China-developed immunology and oncology candidates create both licensing income and potential global clinical assets.
2142.HK impact map — “China Becomes Pharma's Global R&D Engine”
How this story travels from the headline to 2142.HK’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading 2142.HK impact map…
Price history, marked with story events
May 28, 2026 – Aug 28, 2026 · 65 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
China Becomes Pharma's Global R&D Engine
Western drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
BULL side — Harbour BioMed's antibody-discovery platforms and China-developed immunology and oncology candidates create both licensing income and potential global clinical assets.
Read the full China Becomes Pharma's Global R&D Engine story